Inlyta and Compazine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Inlyta (axitinib) and Compazine (prochlorperazine maleate). Common drug interactions include drug ineffective among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Inlyta and Compazine. It is created by eHealthMe based on reports of 49 people who take the same drugs from the FDA, and is updated regularly.

What is Inlyta?

Inlyta has active ingredients of axitinib. eHealthMe is studying from 17,662 Inlyta users. Check the latest studies of Inlyta.

What is Compazine?

Compazine has active ingredients of prochlorperazine maleate. It is often used in nausea and vomiting. eHealthMe is studying from 13,646 Compazine users. Check the latest studies of Compazine.

On Aug, 02, 2026

49 people who take Inlyta and Compazine together, and have interactions are studied.

What are the common drug interactions of Inlyta and Compazine, by gender? *:

female:

Drug ineffective
Epistaxis (bleed from the nose)
Hand-foot-and-mouth disease
Hot flush (sudden feelings of heat)
Hypersensitivity
Malaise (a feeling of general discomfort or uneasiness)
Muscle spasms (muscle contraction)
Pneumonia
Pruritus (severe itching of the skin)
Stomatitis (inflammation of mucous membrane of mouth)

male:

Diarrhoea
Decreased appetite
Intestinal ischaemia (decreased supply of oxygenated blood to the intestines)
Lower gastrointestinal haemorrhage (bleeding in the large intestine, rectum, or anus is called lower gi bleeding)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Stupor (lack of critical cognitive function and level of consciousness)
Dysphonia (speech disorder attributable to a disorder of phonation)
Blood pressure increased
Headache (pain in head)
Asthenia (weakness)

What are the common drug interactions of Inlyta and Compazine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Death
Malaise (a feeling of general discomfort or uneasiness)
Drug ineffective
Neoplasm progression (growth of tumour)

40-49:

n/a

50-59:

Hemiplegia (paralysis of one side of the body)
Malignant neoplasm progression (cancer tumour came back)
Osteonecrosis (death of bone)
Skin disorder (skin disease)
Skin exfoliation (removal of the oldest dead skin cells)
Urinary bladder haemorrhage (urinary bladder bleeding)
Blood pressure increased
Cholecystitis (infection of gallbladder)
Dysphonia (speech disorder attributable to a disorder of phonation)
Enteritis (inflammation of the small intestine)

60+:

Diarrhoea
Decreased appetite
Hypertension (high blood pressure)
Pain
Skin exfoliation (removal of the oldest dead skin cells)
Renal cell carcinoma (a kidney cancer)
Abdominal pain
Asthenia (weakness)
Back pain
Burning sensation

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 33 people, 67.35%
Nausea (feeling of having an urge to vomit): 17 people, 34.69%
Pain: 9 people, 18.37%
High Blood Pressure: 7 people, 14.29%
Diarrhea: 4 people, 8.16%
Diabetes: 4 people, 8.16%
Constipation: 4 people, 8.16%
Stress And Anxiety: 3 people, 6.12%
Oral Pain: 3 people, 6.12%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 3 people, 6.12%

* Approximation only. Some reports may have incomplete information.

Do you take Inlyta and Compazine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously